Giving Voice to Canadians Concerned About Breast Cancer

Education

Our Voices Blog

Research Updates from ASCO 2019

There’s always interesting research updates released at the American Society of Clinical Oncology Conference – here’s what you need to know. 

Ribociclib improves overall survival for women with HR+ HER2-negative metastatic breast cancer

Adding ribociclib, a CDK 4/6 inhibitor, to standard hormonal therapy improves overall survival for young premenopausal women. 70% of women who took the combination therapy were alive after 42 months in comparison to 46% of women treated with just hormone therapy.
Read more

Metastatic breast cancer patients with high tumour mutational burden respond well to Pembrolizumab as a monotherapy

Tumour mutational burden (TMB) is a measurement of mutations in the tumour cells. Patients with metastatic breast cancer who had between 9 and 37 mutations found through genomic testing showed a median progression-free survival of 10.6 weeks and overall survival of 31.6 weeks.  
Read more

Primary data from study of Imprime PGG combined with pembrolizumab

The Phase 2 IMPRIME 1 study consisted of 44 metastatic triple negative breast cancer patients who had been previously treated. It combined Imprime PGG, an immunotherapy, with pembrolizumab.  It found an overall response rate of 15.9% and a 13.7-month median overall survival. 64.2% of patients were alive at 12 months.
Read more

Margetuximab improved progression free survival for HER2+ metastatic breast cancer

Previously treated HER2+ patients in the phase II SOPHIA trial were treated with HER2 targeted antibody, margetuximab. They showed a median progression free survival (PFS) of 5.8 months compared to 4.9 months for those treated with trastuzumab. For patients who carried the CD16A-F allele, the median PFS was 6.9 months compared to trastuzumab patients at 5.1 months.
Read more

Combining capivasertib to fulvestrant found progression free survival to double for metastatic ER+ breast cancer patients

This phase II trial focused on postmenopausal metastatic or locally advanced breast cancer patients who were ER+. PFS improved from 4.8 months to 10.3 months by adding an AKT pathway inhibitor, capivasertib, to fulvestrant treatment. Adverse events and side effects also increased, including diarrhea, rash and hyperglycemia.
Read more

Photo by Lance Anderson on Unsplash